Dyne Therapeutics Reports Q1 2022 Net Loss of $35.6M and Provides Clinical Milestones

Dyne Therapeutics, Inc.

2023-Q1 EPS reported -$0.69

Net loss for Q1 2022 was $35.6 million ($0.69 per share) vs. $25.0 million in Q1 2021.
Cash, cash equivalents and marketable securities totaled $323.2 million as of March 31, 2022.
R&D expenses were $28.2 million in Q1 2022, up from $18.6 million in Q1 2021.
Company plans to submit IND response for DYNE-251 in DMD and regulatory filings for DYNE-101 in DM1 in Q2 2022.
Initiation of multiple ascending dose clinical trials for DYNE-251 and DYNE-101 anticipated in mid-2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.